Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
about
Isavuconazole: A New Broad-Spectrum Triazole Antifungal AgentActivity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Candida glabrata--unique features and challenges in the clinical management of invasive infections.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.In vitro activity of five antifungal agents against Candida albicans isolates, Sari, IranCryptococcus neoformans in the respiratory tract of squirrels, Callosciurus finlaysonii (Rodentia, Sciuridae).Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
P2860
Q28082019-EBDEAFF0-0F57-48CE-A301-6CAABB292FA5Q36439061-F031AE7E-12C7-4E4B-A8FD-347A97C74180Q37580801-141DAF70-FD3F-47FA-BA4F-339F46EBEBA3Q38285488-4C5A1688-2398-4FD0-A545-27E3B3877484Q38534865-CE2CA490-CF43-4B89-B2B8-518D36103D67Q38553440-55611E40-87CA-4443-938D-EB2BD2905E9DQ38829932-2B828961-01E7-4846-8518-B5F192F843C2Q38939506-E76C1E5E-6497-4079-8C55-205F1B31C0D0Q39459173-56BA9D5C-5D05-4CCC-91A0-395B0F20A047Q40674942-4CF651F2-3108-4E03-A0EA-1193909482EBQ46257853-A223EFF9-1511-447E-BACE-8F9665C6DD52Q53779321-6A9C36CC-C8CB-424E-9A16-1329DA27F497Q54214603-BFD71F80-EC44-43DA-8C76-400AD9DAE198Q58701180-8954DCF8-D718-4516-925E-649ED6E8EA80
P2860
Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Isavuconazole and nine compara ...... epidemiological cutoff values.
@en
Isavuconazole and nine compara ...... epidemiological cutoff values.
@nl
type
label
Isavuconazole and nine compara ...... epidemiological cutoff values.
@en
Isavuconazole and nine compara ...... epidemiological cutoff values.
@nl
prefLabel
Isavuconazole and nine compara ...... epidemiological cutoff values.
@en
Isavuconazole and nine compara ...... epidemiological cutoff values.
@nl
P2093
P2860
P1433
P1476
Isavuconazole and nine compara ...... epidemiological cutoff values.
@en
P2093
Paul R Rhomberg
Rachel R Dietrich
Ronald N Jones
Shawn A Messer
P2860
P2888
P356
10.1007/S11046-014-9772-2
P577
2014-06-21T00:00:00Z